Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3775695 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692875 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692872 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL5163322 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372670 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL25212993 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL8440714 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL260176 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL20917176 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372534 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115820503-B | Preparation method of fecal bacteria for intestinal flora transplantation | 山东省大健康精准医疗产业技术研究院 | 2026-05-15 | — | — | CN | claimed |
| EP-4704819-A1 | NANOPARTICLE COMPOSITION FOR OXYGEN DELIVERY | Swaza Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| CN-120204052-B | Composition for biomimetic remineralization of dentin and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2026-02-27 | — | — | CN | claimed |
| EP-3342398-B1 | METHOD FOR PREPARING OPHTHALMIC PREPARATION CONTAINING THYMOSIN BETA-4 | HLB THERAPEUTICS CO LTD (KR) | 2026-02-11 | — | — | EP | claimed |
| CN-120117663-A | Cobalt-based compound composite material and preparation method and application thereof | 海南大学 | 2025-06-10 | — | — | CN | claimed |
| US-20250176532-A1 | BIOLOGICAL SAMPLE PRESERVATIVE, PRODUCTION METHOD OF BIOLOGICAL SAMPLE PRESERVATIVE, PRESERVATION METHOD OF BIOLOGICAL SAMPLE, AND KIT FOR PRESERVING BIOLOGICAL SAMPLE | BLUE INDUSTRIES INC. (JP) | 2025-06-05 | — | — | US | claimed |
| CN-119185194-B | Vitamin D3 injection pharmaceutical composition and application thereof | 安徽益普克医药科技发展有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2025083738-A1 | PHARMACEUTICAL CARRIER AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIVERSITÀ DEGLI STUDI DI BARI "ALDO MORO" (IT) | 2025-04-24 | — | — | WO | claimed |
| US-20250082623-A1 | COMPOSITIONS CONTAINING FEXOFENADINE | OPELLA HEALTHCARE GROUP SAS (FR) | 2025-03-13 | — | — | US | claimed |
| EP-4512404-A1 | COMPOSITION FOR OPHTHALMIC USE CONTAINING SEPETAPROST | Santen Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | claimed |
| EP-1133549-A1 | DETERGENT COMPOSITIONS | UNILEVER PLC (GB) | 2001-09-19 | — | — | EP | claimed |
| US-6242403-B1 | TABLET FROM COMPACTED (A) PARTICLES CONTAINING AT LEAST 60% BY WEIGHT OF NON-SOAP ANIONIC DETERGENT AND (B) PARTICLES CONTAINING AT LEAST 80% OF THEIR OWN WEIGHT OF ONE OR MORE WATER-SOLUBLE MATERIALS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2001-06-05 | — | — | US | claimed |
| EP-1071742-A1 | WATER-SOFTENING AND DETERGENT COMPOSITIONS | UNILEVER PLC (GB) | 2001-01-31 | — | — | EP | claimed |
| EP-1027421-A1 | DETERGENT COMPOSITIONS IN TABLET FORM | UNILEVER PLC (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-2000032740-A1 | DETERGENT COMPOSITIONS IN TABLET FORM | UNILEVER PLC (GB) | 2000-06-08 | — | — | WO | claimed |
| WO-2000032741-A1 | DETERGENT COMPOSITIONS | UNILEVER PLC (GB) | 2000-06-08 | — | — | WO | claimed |
| WO-1999053014-A1 | WATER-SOFTENING AND DETERGENT COMPOSITIONS | UNILEVER PLC (GB) | 1999-10-21 | — | — | WO | claimed |
| US-5929276-A | HEATING CRYSTALLINE HYDRATED TRISODIUM CITRATE UNDER CONTROLLED CONDITIONS OF TEMPERATURE AND HEATING RATE TO REMOVE WATER OF HYDRATION | JUNGBUNZLAUER AUSTRIA AG (AT) | 1999-07-27 | — | — | US | claimed |
| WO-1999020730-A1 | DETERGENT COMPOSITIONS IN TABLET FORM | UNILEVER PLC (GB) | 1999-04-29 | — | — | WO | claimed |
| US-5595687-A | INJECTABLE FLUOROCARBON EMULSION USEFUL IN CORONARY ANGIOPLASTY, CANCER THERAPY | THOMAS JEFFERSON UNIVERSITY (US) | 1997-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082623-A1 | COMPOSITIONS CONTAINING FEXOFENADINE | HRH2, IL5, HRH1 | CA4 203/4885CASP1 3314/4885FFAR3 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.